Prof. Sir Mike Brady

An Emeritus Professor of Oncological Imaging at the University of Oxford, he was elected a Fellow of the Royal Academy of Engineering (FREng) in 1992 and a Fellow of the Royal Society in 1997.

As well as a highly distinguished career in research, Mike has founded a number of spin-out companies, including Matakina and ScreenPoint, Mirada Medical, and Perspectum Diagnostics. He has been an invaluable advisor and strong supporter of our technology throughout its development.

Prof Ahmed Ahmed

Consultant Gynaecological Oncology Surgeon, Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine. Ahmed works in early detection of ovarian cancer and is the co-founder of Singula Bio, an Oxford spin out providing patient specific cancer therapy. Ahmed is providing invaluable help with moving our technology into ovarian cancer diagnosis.

Prof. Pinar Ozcan

Professor of Entrepreneurship and Innovation, and academic director of the Oxford Saïd Entrepreneurship Centre. Pinar is a founding partner of Blanchard International Turkey. She was selected to the Top 40 Business School Professors under 40 list by Poets and Quants and included in the Thinkers 50 list for emerging thinkers, the British Academy Mid-Career Fellows, and the Global Women in Fintech Powerlist for 2021.

Prof. Kypros Nicolaides

World renown fetal medicine specialist and Founder and Chairman of the UK Charity, the Fetal Medicine Foundation (FMF).

He is one of the pioneers of fetal medicine and his discoveries have revolutionised the field. He proposed a new model of pregnancy care – “Turning the Pyramid of Prenatal Care”. This aims to assess the risk for most of the relevant pregnancy complications affecting mother and unborn child at 11-13 weeks of gestation and, on the basis of such risks, provide personalised care to reduce an adverse outcome. He has supported our placental imaging research for more than 10 years, providing invaluable help and advice.

Ali Abtahi

Ali is a lawyer with a background in public health. He is keenly interested in utilising his educational background and professional experience to improve public health and to assist companies that have developed transformative health and medical technologies.